The DOI matches its Crossref record; 34 of the 38 references it cites were found in a registry or an index; 28 of the 32 sources its claims cite were checked for support.
Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man
Open accessAbstract
We characterized the world’s second case with ascertained extreme resilience to autosomal dominant Alzheimer’s disease (ADAD). Side-by-side comparisons of this male case and the previously reported female case with ADAD homozygote for the APOE3 Christchurch ( APOECh ) variant allowed us to discern common features. The male remained cognitively intact until 67 years of age despite carrying a PSEN1 -E280A mutation. Like the APOECh carrier, he had extremely elevated amyloid plaque burden and limited entorhinal Tau tangle burden. He did not carry the APOECh variant but was heterozygous for a rare variant in RELN (H3447R, termed COLBOS after the Colombia–Boston biomarker research study), a ligand that like apolipoprotein E binds to the VLDLr and APOEr2 receptors. RELN-COLBOS is a gain-of-function variant showing stronger ability to activate its canonical protein target Dab1 and reduce human Tau phosphorylation in a knockin mouse. A genetic variant in a case protected from ADAD suggests a role for RELN signaling in resilience to dementia.
Overview
CoChat Summary
TL;DR
A male carrier of the PSEN1-E280A mutation remained cognitively intact until age 67 and was found to be heterozygous for a rare RELN variant, H3447R (RELN-COLBOS), rather than the APOE3 Christchurch variant. RELN-COLBOS behaved as a gain-of-function variant in vitro and in knockin mice, suggesting a role for RELN signaling in resilience to autosomal dominant Alzheimer’s disease.
Key findings
- The male PSEN1-E280A carrier had very high amyloid burden (PiB DVR = 1.77) compared with younger impaired carriers from the kindred (mean DVR = 1.51 ± 0.13), but relatively limited entorhinal cortex Tau pathology (FTP SUVR = 1.34), with inferior temporal SUVR = 1.78, posterior cingulate SUVR = 1.51 and precuneus SUVR = 1.49.
- Postmortem neuropathology showed severe AD changes (brain weight = 745.4 g, CERAD C, Braak VI, Thal phase 5) with extensive amyloid and Tau pathology, yet the entorhinal cortex showed the highest neuronal density with low Aβ and pTau among compared cases; RELN-COLBOS had more pTau pathology than the APOECh case except in specific regions.
- RELN-COLBOS increased Dab1 phosphorylation versus wild-type RELN in primary mouse cortical neurons (P = 0.0246); in male knockin mice it enhanced pDab1 (P = 0.0284 for WT/WT vs H3448R/H3448R; P = 0.0037 for WT/H3448R vs H3448R/H3448R), reduced human Tau pT205 in hippocampus (P = 0.022) and improved tail elevation score in Tau-P301L mice (P = 0.0305).
- The proband’s sister, also heterozygous for RELN-COLBOS and PSEN1-E280A, had MCI onset 14 years and dementia onset 12 years later than expected for this population, although she was less protected than her brother.
Methods
- Case report within the Colombia–Boston biomarker research study (COLBOS), with clinical assessments and in vivo neuroimaging using PiB and FTP PET for amyloid and Tau, FDG PET for glucose metabolism, and MRI for hippocampal and whole-brain volume; PET data were expressed as DVR or SUVR with cerebellar gray matter reference.
- Genetic and molecular studies included WES, WGS and Genomizer analysis; primary mouse cortical neuron culture; heparin chromatography, HPLC, SPR, ITC, BLI and NMR; and a RELN-H3448R knockin mouse model crossed with the Tau P301L model for biochemical, behavioral and immunohistochemical analyses.
- Neuropathology included postmortem brain examination after a 210-min postmortem interval, with immunohistochemistry for Aβ, pTau, Iba1, GFAP, C-terminal Reelin and APOE, neuronal counting, and statistical analyses using Kruskal–Wallis, ANOVA, t-tests and Spearman correlation as appropriate.
Limitations
- The paper states that comparative neuropathology was conducted in a relatively low number of cases, so results should not be considered definitive and are only helpful to generate hypotheses; it also states that other factors, including additional variants, cannot be ruled out as contributors to the resilience phenotype.
- The paper notes that the female sibling had a severe head injury, depression and hypothyroidism, which may have affected her clinical profile, and that RELN-specific sexual dimorphism may have contributed to her distinct features; it also notes that the hypermorphic effect of RELN is mild.
- Evident from the text: human evidence rests on one male case plus one sibling, so causality is not established; in mice, homozygosity was required to detect changes in Dab1 and GSK3β activity, and increased Dab1 phosphorylation and enhanced RELN oligomerization were observed only in male mice, limiting direct inference for heterozygous humans.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
















Verification
Claims the paper makes
21 Valid · 3 Not valid · 4 Not checked · 69 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“These imaging findings suggest that in this patient and in the APOECh homozygote case2, protection against ADAD dementia occurred even in the face of high amyloid burden (Fig. 1a,b).”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
What the sources say
- Supportedcites [2] Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680–1683 (2019). source
The paper reports that the APOE3-Christchurch homozygote remained resistant to the clinical onset of ADAD dementia into her seventies. In the passage labeled Abstract, it also reports unusually high amyloid-β plaque burden on PET (DVR 1.96), supporting the claim about this cited case; the citation does not need to establish the findings for the citing paper’s other patient. (LLM, conf=0.94)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The C-terminal region of RELN (CTR-RELN), where the H3447R variant is located, modulates signaling indirectly via interactions with previously unidentified coreceptors on cell membranes10.”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
What the sources say
- Partly supportedcites [10] Nakano, Y. et al. The extremely conserved C-terminal region of Reelin is not necessary for secretion but is required for efficient activation of downstream signaling. J. Biol. Chem. 282, 20544–20552 (2007). sourceExperimental — accuracy not yet measured
The Discussion (page not supplied) proposes that the CTR binds an unidentified molecule on the cell membrane, stabilizing Reelin’s receptor interaction and strengthening signaling. It presents the coreceptor interaction as a plausible model, not an established mechanism, whereas the citing sentence states it as fact. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“However, he had relatively limited Tau pathology in the entorhinal cortex (ERC) (SUVR = 1.34; Fig. 1a,c) and in other neocortical regions, such as the posterior cingulate cortex (PCC) and precuneus (SUVR PCC = 1.51; SUVR precuneus = 1.49; Fig. 1a)”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
What the sources say
- Could not verifycites [3] Quiroz, Y. T. et al. Association between amyloid and tau accumulation in young adults with autosomal dominant Alzheimer disease. JAMA Neurol. 75, 548–556 (2018). sourceExperimental — accuracy not yet measured
The Regional 18F FTP Binding section reports group-level SUVRs and describes binding in the posterior cingulate/precuneus, but does not report the stated values for a male case. Searches for the three SUVR values and for a male case found no matching passage in our copy. (LLM, conf=0.73)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“because the encoded protein RELN modulates Tau phosphorylation4 and is functionally closely related to APOE, the gene mutated in the other case with extreme protection against ADAD2.”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
What the sources say
- Supportedcites [2] Arboleda-Velasquez, J. F. et al. Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat. Med. 25, 1680–1683 (2019). source
Citation 2 is attached to the identification of APOE as the gene mutated in the other case with extreme protection against ADAD. The paper’s Abstract describes a homozygous APOE3 Christchurch subject remarkably resistant to clinical ADAD dementia and identifies APOE3ch as the likely genetic modifier. It does not establish the sentence’s separate RELN–APOE functional comparison. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“because the encoded protein RELN modulates Tau phosphorylation4 and is functionally closely related to APOE, the gene mutated in the other case with extreme protection against ADAD2.”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
What the sources say
- Supportedcites [4] Hiesberger, T. et al. Direct binding of Reelin to VLDL receptor and ApoE receptor 2 induces tyrosine phosphorylation of disabled-1 and modulates tau phosphorylation. Neuron 24, 481–489 (1999). source
The Discussion reports tau hyperphosphorylation in reeler mice and says this suggests that tau phosphorylation is regulated, directly or indirectly, by the Reelin signaling pathway. That supports the attributed claim that RELN modulates tau phosphorylation; it does not establish a direct effect. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
56 more claims · 9 with their cited sources checked
Create a free account to see all 97 claims and every source verdict.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 18
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The individual developed mild cognitive impairment approximately two decades later than the typical onset for carriers of this autosomal dominant AD mutation and exhibited relatively low tau pathology.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, rare cases of individuals who have one of these mutations and do not develop dementia symptoms until late life have recently been reported.”
From 2024 Alzheimer's disease facts and figures (2024) · cites this paper as [104]
The cited source says what the claim attributes to it.
In the citing paper
“Biochemical and functional studies revealed that the RELN variant enhances Reelin signaling and limits tau pathology, which may underlie the observed cognitive resilience.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, a rare gain‐of‐function variant in RELN was identified in a patient with an autosomal dominant AD‐causing mutation, and it was associated with resilience against cognitive impairment.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [84]
The cited source says what the claim attributes to it.
In the citing paper
“Notably, the RELN variant enhanced its binding to glycosaminoglycans (GAGs) and NRP1, and the APOE variant decreased binding to GAGs, potentially affecting their ability to compete for receptor binding69,70.”
From Single-cell multiregion dissection of Alzheimer’s disease (2024) · cites this paper as [70]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Methods > Statistical analysis
“The neuropathological data (Fig. 2) were analyzed and graphs were generated with Prism 8 (v.8.1.1) and the R (v.3.6.3) statistical software (R Foundation for Statistical Computing).”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
“Figure: Fig. 2 The RELN-H3448R variant enhances Dab1 signaling and the affinity of CTR-RELN to heparin.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Methods > Western blotting
“The blots are presented in Figs. 3a and 4a.”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
“a,b, Representative in silico models depicting the orientation of basic amino acids in the heparin-binding motif (highlighted with colors) using the WT CTR-RELN NMR structure (a).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Methods > Statistical analysis
“For the SPR data (Fig. 3c and Supplementary Fig. 4), we verified the accuracy of the results with a chi-squared test”
§ Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man > Results > Case report
“c, RELN peptide variant sequences used for the HPLC analysis.”
Citations
Cites
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease
Gómez-Isla, T., Price, J. L., McKeel Jr., D. W., Morris, J. C., Growdon, J. H., & Hyman, B. T. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-14-04491.1996 · Cited by 1,796
A protein related to extracellular matrix proteins deleted in the mouse mutant reeler
D'Arcangelo, G., G. Miao, G., Chen, S.-C., Scares, H. D., Morgan, J. I., & Curran, T. (1995) · Nature · doi:10.1038/374719a0 · Cited by 1,748
Lewis, J., McGowan, E., Rockwood, J., Melrose, H., Nacharaju, P., Van Slegtenhorst, M., Gwinn-Hardy, K., Murphy, M. P., Baker, M., Yu, X., et al. (2000) · Nature Genetics · doi:10.1038/78078 · Cited by 1,371
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986
Self-citationHiesberger, T., Trommsdorff, M., Howell, B. W., Goffinet, A., Mumby, M. C., Cooper, J. A., & Herz, J. (1999) · Neuron · doi:10.1016/s0896-6273(00)80861-2 · Cited by 916
Reelin Is a Ligand for Lipoprotein Receptors
D'Arcangelo, G., Homayouni, R., Keshvara, L., Rice, D. S., Sheldon, M., & Curran, T. (1999) · Neuron · doi:10.1016/s0896-6273(00)80860-0 · Cited by 808
Sex-specific genetic architecture of human disease
Ober, C., Loisel, D. A., & Gilad, Y. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2415 · Cited by 787
Evolution of the neuropathology of Alzheimer's disease
Braak, H., & Braak, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05866.x · Cited by 710
Cited by
2024 Alzheimer's disease facts and figures
(2024) · Alzheimer's & Dementia · doi:10.1002/alz.13809 · Cited by 2,536
2025 Alzheimer's disease facts and figures
(2025) · Alzheimer's & Dementia · doi:10.1002/alz.70235 · Cited by 474
Alzheimer’s disease: insights into pathology, molecular mechanisms, and therapy
Zheng, Q., & Wang, X. (2025) · Protein & Cell · doi:10.1093/procel/pwae026 · Cited by 410
Single-cell multiregion dissection of Alzheimer’s disease
Mathys, H., Boix, C. A., Akay, L. A., Xia, Z., Davila-Velderrain, J., Ng, A. P., Jiang, X., Abdelhady, G., Galani, K., Mantero, J., et al. (2024) · Nature · doi:10.1038/s41586-024-07606-7 · Cited by 343
“Notably, the RELN variant enhanced its binding to glycosaminoglycans (GAGs) and NRP1 , and the APOE variant decreased binding to GAGs, potentially affecting their ability to compete for receptor binding 69,70 .”
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials
Boxer, A. L., & Sperling, R. (2023) · Cell · doi:10.1016/j.cell.2023.09.023 · Cited by 197
Self-citation
Metadata
- Authors
- Lopera, F., Marino, C., Chandrahas, A. S., O’Hare, M., Villalba-Moreno, N. D., Aguillon, D., Baena, A., Sanchez, J. S., Vila-Castelar, C., Ramirez Gomez, L., Chmielewska, N., Oliveira, G. M., Littau, J. L., Hartmann, K., Park, K., Krasemann, S., Glatzel, M., Schoemaker, D., Gonzalez-Buendia, L., Delgado-Tirado, S., Arevalo-Alquichire, S., Saez-Torres, K. L., Amarnani, D., Kim, L. A., Mazzarino, R. C., Gordon, H., Bocanegra, Y., Villegas, A., Gai, X., Bootwalla, M., Ji, J., Shen, L., Kosik, K. S., Su, Y., Chen, Y., Schultz, A., Sperling, R. A., Johnson, K., Reiman, E. M., Sepulveda-Falla, D., Arboleda-Velasquez, J. F., & Quiroz, Y. T.
- Affiliations
- Universidad de Antioquia (CO)
- Massachusetts Eye and Ear Infirmary (US)
- Harvard University (US)
- University Medical Center Hamburg-Eppendorf (DE)
- University of Southern California (US)
- Children's Hospital Los Angeles (US)
- University of California, Santa Barbara (US)
- Banner Alzheimer’s Institute (US)
- Brigham and Women's Hospital (US)
- Translational Genomics Research Institute (US)
- Corresponding author
- Quiroz, Yakeel T.
- ORCID
- Lopera, Francisco
- Marino, Claudia
- Chandrahas, Anita S.
- O’Hare, Michael
- Aguillon, David
- Baena, Ana
- Sanchez, Justin S.
- Vila-Castelar, Clara
- Chmielewska, Natalia
- Oliveira, Gabriel M.
- Littau, Jessica Lisa
- Krasemann, Susanne
- Glatzel, Markus
- Arevalo-Alquichire, Said
- Amarnani, Dhanesh
- Kim, Leo A.
- Mazzarino, Randall C.
- Gordon, Harper
- Bocanegra, Yamile
- Gai, Xiaowu
- Bootwalla, Moiz
- Ji, Jianling
- Kosik, Kenneth S.
- Su, Yi
- Chen, Yinghua
- Schultz, Aaron
- Sperling, Reisa A.
- Johnson, Keith
- Reiman, Eric M.
- Sepulveda-Falla, Diego
- Arboleda-Velasquez, Joseph F.
- Quiroz, Yakeel T.
- Venue
- Nature Medicine
- Published
- 2023-05
- Volume
- 29
- Issue
- 5
- Pages
- 1243-1252
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC10202812
- OpenAlex
- W4376608964
- Semantic Scholar
- 114afac82cf65e63c8418b46306010d3d5bf7719
- Cited by
- 192
- References
- 38
- Citations by year
- 2026: 37 · 2025: 66 · 2024: 55 · 2023: 33
- FWCI
- 33.90
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 14 d)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UA Campus Repository (The University of Arizona) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Greater South Information System
- Funders
- National Science Foundation (1745303)
- W. M. Keck Foundation
- Alzheimer's Association (2019A005859)
- American Heart Association (20POST35110047)
- Broad Institute
- Open Philanthropy Project
- Good Ventures Foundation
- Deutsche Forschungsgemeinschaft (SFB 877)
- Bundesministerium für Bildung und Forschung
- NOMIS Stiftung
- Werner Otto Stiftung
- National Institutes of Health (DGE1745303, DP5OD019833, AG072980)
- National Institute on Aging (RF1AG041705, NS100121, R01AG054671, K99AG073452, RF1AG077627, NS110048, P30AG072980, R01AG058468)
- National Eye Institute (R01EY027739)
- National Institute of Neurological Disorders and Stroke (RF1NS110048, RM1NS132996, UH3NS100121)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- autosomal dominant Alzheimer's disease, disease resilience, reelin, PSEN1 E280A mutation, amyloid plaques, tau tangles, entorhinal cortex, tau phosphorylation, gain-of-function mutations, cognitive aging
- MeSH terms
- Reelin Protein, Alzheimer Disease, Animals, Female, Heterozygote, Humans, Male, Nerve Tissue Proteins, Signal Transduction, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. https://app.cochat.ai/papers/10.1038/s41591-023-02318-3
- The paper
- Lopera, F., Marino, C., Chandrahas, A. S., O’Hare, M., Villalba-Moreno, N. D., Aguillon, D., Baena, A., Sanchez, J. S., Vila-Castelar, C., Ramirez Gomez, L., Chmielewska, N., Oliveira, G. M., Littau, J. L., Hartmann, K., Park, K., Krasemann, S., Glatzel, M., Schoemaker, D., Gonzalez-Buendia, L., . . . Quiroz, Y. T. (2023). Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man. Nature Medicine. https://doi.org/10.1038/s41591-023-02318-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.